Preliminary report on the effect of brachytherapy on expression of p53, bcl-2 and apoptosis in squamous cell carcinoma of the oesophagus

South African Journal of Surgery

Volumn 41, Issue 1, 2003, Pages 14-20

  Sur, Monalisa ^a   Sur, Ranjan K ^a   Cooper, Kum ^a   Bizos, Damon ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYL RADICAL; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE; GENE INDUCTION; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; KERATIN GENE; KERATINIZATION; MALE; METASTASIS; PROTEIN EXPRESSION; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TUMOR NECROSIS;

ADULT; AGED; APOPTOSIS; BIOPSY; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENE EXPRESSION; GENES, BCL-2; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 0037308610     PISSN: 00382361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Sur RK, Levin CV. Brachytherapy for oesophageal cancer. S Afr J Surg 1995; 33: 49-51.
2. Sur RK, Donde B, Levin CV, Mannel A. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced oesophageal cancer. Int J Radiat Oncol Biol Phys 1998; 40: 447-453.
3. Sur M, Sur RK, Cooper K, Levin V, Bizos D, Dubazana N. Morphologic alterations in esophageal squamous cell carcinoma after preoperative high dose rate intraluminal brachytherapy. Cancer 1996; 77: 2200-2205.
4. Koehler RE, Moss AA, Marguilis AR. Early radiographic manifestations of carcinoma of the esophagus. Radiology 1976; 119: 1-5.
5. Sur M, Taylor L, Cooper K, Sur RK. Lack of correlation of p glycoprotein expression with response to MIC chemotherapy in esophageal cancer. J Clin Pathol 1997; 50: 534.
6. Zenbetti GP, Levine AJ. A comparison of the biologic activities of wild type and mutant p53. FASEB J 1993; 7: 855.
7. Chang F. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol 1993; 88: 174-186.
8. H on chromosome 14 near a transcriptional unit on chromosome 18. Cell 1985; 41: 899-906.
9. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of c-DNAs for bcl2 and a hybrid bcl-2 immunoglobulin transcript resulting from the t(14; 18) translocation. Cell 1986; 47: 19-28.
10. Landanyi M, Wang S. Detection of rearrangements of the bcl2 major breakpoint region in follicular lymphomas. Correlation of polymerase chain reaction results with Southern blot analysis. Diagn Mol Pathol 1992; 1: 31-35.
11. Chen-Levy Z, Nourse J, Cleary ML. The bcl2 candidate proto-oncogene is a 24 kD integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14; 18) translocation. Mol Cell Biol 1989; 9: 701-710.
12. Pezzella F, Turley H, Kuzu I. bcl2 protein expression in non-small cell lung carcinoma. Immunohistochemical evidence for abnormal expression and correlation with survival. N Engl J Med 1993; 329: 690-694.
13. Hockenberry DM. bcl2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241.
14. Kerr JFR, Harmon BV. Definition and incidence of apoptosis: A historical perspective. In: Tomey LD, Cope FO, eds. Apoptosis: The Molecular Basis of Cell Death. Coldspring Harbor, NY: Coldspring Harbor Laboratory Press, 1991.
15. Vaux DL, Cory S, Admas JM. bcl2 gene promotes haemopoetic cell survival and cooperates with c-myc to immortalize pre- B cells. Nature 1988; 335: 440-442.
16. Chiarugi V, Ruggiero M. Role of three cancer 'mastergenes' p53, bcl2 and c-myc on the apoptotic process. Tumori 1996; 82: 205-209.
17. Fisher AM, Rucker N, Wong S, Gomer CJ. Differential photosensitivity in wild-type and mutant p53 human colon carcinoma cell lines. J Photochem Photobiol B 1998; 42: 104-107.
18. Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996; 2: 1649-1657.
19. Matsubara H, Kimura M, Sugaya M, et al. Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells. Int J Oncol 1999; 14: 1081-1085.
20. Coggi G, Bosari S, Roncalli M, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997; 79: 425-432.
21. Wang LD, Zhou Q, Hong JY, Qiu SL, Yang CS. p53 protein accumulation and gene mutations in multifocal esophageal pre cancerous lesions from symptom free subjects in high incidence area for esophageal cancer in Henan, China. Cancer 1996; 77: 1244-1249.
22. Muro K, Ohtsu A, Boku N, et al. Association of p 53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemo radiotherapy. Jpn J Clin Oncol 1996; 26: 65-69.
23. Puglisi F, Loreto CD, Avellini C, Fongione S, Cacitti V, Beltrami CA. Expression of p 53 and bcl 2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the esophagus. J Clin Pathol 1996; 49: 456-459.
24. Pomp J, Davellar J, Blom J, et al. Radiotherapy for esophageal carcinoma: The impact of p53 on treatment outcome. Radiother Oncol 1998; 46: 179-184.
25. Nabeya Y, Loganzo F jun., Maslak P, et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts the sensitivity to chemotherapeutic agents. Int J Cancer 1995; 64: 37-46.
26. Haimovitz Friedman A, Kolesnick RN, Fuks Z. Modulation of the apoptotic response: Potential for improving the outcome in clinical radiotherapy. Sem Radiat Oncol 1996; 6: 273-283.
27. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379: 88-91.
28. Kinzler KW, Vogelstein B. Life (and death) in a malignant tumor. Nature 1996; 379: 19-20.
29. Allsopp TE, Wyatt S, Paterson HF, Davies AM. The proto oncogene bcl 2 can selectively rescue neutrophic factor-dependent neurons from apoptosis. Cell 1993; 73: 295-307.
30. Vaux DL, Cory S, Adams JM. Bcl 2 promotes the survival of hemopoietic cells and co-operates with c - myc to immortalize pre B cells. Nature 1988; 335: 440-442.
31. Strasser A, Harris AW, Jacks T. DNA damage can induce apoptosis in proliferating lymphoid cells via P 53 independent mechanisms inhabitable by bcl-2. Cell 1994; 79: 329-339.
32. Miyashita T, Reed JC. Bcl2 oncoprotein blocks chemotherapy induced apoptosis in a leukemia cell line. Blood 1993; 81: 151-157.
33. Kernohana NM, Cox LS. Regulation of apoptosis by bcl 2 and its related proteins: Immunochemical challenges and therapeutic implications. J Pathol 1996; 179: 1-3.